CTOs on the Move


 
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health. We partner with best-in-class biotechnology companies to apply their deep expertise and extensive capabilities for the discovery and development of novel and advanced veterinary biotherapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.invetx.com
  • 201 Washington Street Suite 3930
    Boston, MA USA 02108
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Invetx raised $15M on 02/24/2020
Invetx raised $60.5M on 05/10/2022

Similar Companies

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celcuity

Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.

Schleicher and Schuell BioScience

Schleicher and Schuell BioScience is a Keene, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tetracore

At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.

Cellarity

Cellarity`s mission is to fundamentally transform the way medicines are created through the development of the first full stack digital cell. Founded by Flagship Pioneering in 2017, Cellarity has developed unique capabilities combining high-resolution data, single cell technologies, and machine learning to encode biology, model interventions, and purposefully design breakthrough medicines. By focusing on the cellular changes that underlie disease instead of a single target, Cellarity`s approach uncovers new biology and treatments and is applicable to a vast array of disease areas. The company currently has programs underway in metabolic disease, hematology, immuno-oncology, and respiratory disease. The company has raised $123 million as part of a Series B funding round with contributions from funds and accounts managed by Blackrock, The Baupost Group, Banque Pictet on behalf of their clients, and eight other investors alongside Flagship Pioneering.